1 Min Read
Jan 9 (Reuters) - Emergent Technologies Inc
* Emergent says Pure MHC, AbbVie will embark on research, license deal to discover peptide targets for use with t-cell receptor therapeutics in cancers Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.